XPO1 and non-Hodgkin lymphoma: In the phase 1 setting, partial response to KPT-335 was observed in dogs with NHL, and unlike previously tested XPO1 inhibitors such as leptomycin B [55], KPT-335 exhibited good tolerability with anorexia and weight loss as the main clinical effects noted [33].